Edwards Lifesciences (EW) director receives 5,127 RSUs in stock grant

Rhea-AI Filing Summary

VALERIANI NICHOLAS J reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Nicholas J. Valeriani received 5,127 restricted stock units as equity compensation. The award was granted on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program and will become fully vested after one year from the grant date or at the next annual stockholders’ meeting, whichever comes first. Following this grant, he directly holds 84,423 shares of common stock. This is a non-cash, routine director compensation grant rather than an open-market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider VALERIANI NICHOLAS J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,127	$0.00	--

Holdings After Transaction: Common Stock — 84,423 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 5,127 restricted stock units Shares held after grant: 84,423 shares Transaction code: Code A (grant/award acquisition) +2 more

5 metrics

RSUs granted 5,127 restricted stock units Equity award granted May 8, 2026

Shares held after grant 84,423 shares Direct common stock holdings after transaction

Transaction code Code A (grant/award acquisition) Non-derivative Form 4 transaction classification

Grant price per share $0.0000 per share Indicates non-cash RSU grant, not a market purchase

Vesting schedule 100% after earlier of 1 year or next annual meeting Footnote F1 vesting terms for RSU grant

Key Terms

restricted stock units, 2020 Nonemployee Directors Stock Incentive Program, Form 4, transaction code A, +1 more

5 terms

restricted stock units financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Nonemployee Directors Stock Incentive Program financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code A regulatory

"transaction_code_description": "Grant, award, or other acquisition""

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VALERIANI NICHOLAS J

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		5,127(1)	A	$0.0000	84,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edwards Lifesciences (EW) director Nicholas Valeriani report in this Form 4?

Nicholas Valeriani reported receiving 5,127 restricted stock units of Edwards Lifesciences common stock as a grant. This award is part of his director compensation and was not an open-market purchase or sale of existing shares.

How many Edwards Lifesciences (EW) shares does Nicholas Valeriani hold after this grant?

After the grant, Nicholas Valeriani directly holds 84,423 shares of Edwards Lifesciences common stock. This total reflects his position following the award of 5,127 restricted stock units reported in the Form 4 filing.

What are the vesting terms of Nicholas Valeriani’s new Edwards Lifesciences RSUs?

The 5,127 restricted stock units granted to Nicholas Valeriani vest 100% after the earlier of one year from the May 8, 2026 grant date or the company’s next annual meeting of stockholders, as described in the footnote to the Form 4.

Were these Edwards Lifesciences (EW) shares bought or sold on the open market?

No, the Form 4 shows a grant coded “A” for 5,127 restricted stock units, indicating a compensation-related award. It is a non-cash acquisition rather than an open-market buy or sell transaction by Nicholas Valeriani.

Under which plan were Nicholas Valeriani’s Edwards Lifesciences RSUs granted?

The 5,127 restricted stock units were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. This plan provides equity-based compensation to nonemployee directors instead of traditional cash-only board fees.